ITL Virginia to support North American roll-out of Endomag’s Sentimag system

Sep 2 2016

ITL Virginia Inc, the US subsidiary of medical design and manufacturing company ITL, will be supporting the North American roll-out of the Sentimag^® system following Endomag’s signing of a major distribution deal. This will include US-based product maintenance, support and servicing training and may eventually extend to manufacturing.

Endomagnetics Sentimag

Long-standing ITL client, Endomag, recently signed a distribution deal with Leica Biosystems to bring the Sentimag^® magnetic surgical guidance system to the US and Canada.

The Sentimag^® system and its implantable magnetic seed, Magseed^®, guide surgeons to cancerous lesions easily and do not require the use of traditional surgical needle wires or radioactive seeds. Similarly, the Sentimag^® system and its injectable iron solution, Sienna^®, is a replacement for the radioactive tracer and blue dye traditionally used in sentinel lymph node biopsies.

The Sentimag^®/Magseed^® system is approved in the U.S. with Sentimag^® having received its CE mark approval in 2010. Sentimag^® has already been used in over 14,000 breast care procedures across Europe with Sienna^®.

Thomas Jull, ITL VA's Vice President, said:

This first step signals a triumph for ITL VA. Back in 2008, ITL helped develop Sentimag^®  in a collaborative R&D project at our UK facility and we have worked with them ever since. This transatlantic deal highlights Endomag’s commitment to expanding their reach with the support and expertise of ITL.

The Sentimag^® system is revolutionary – a US and Canadian distribution deal opens completely new possibilities for patients to benefit from this technology

He added:

This is exactly why we decided to open a US office three years ago, to better support our international customer-base. This deal supports our vision to provide a complete service on both sides of the pond.

Dr Eric Mayes, CEO of Endomag, said:

The design and manufacturing support that we have received from ITL to date has been fundamental to the success of our business and we are delighted to have them supporting us as we take our next big step into the US market.

ITL began operating from Richmond, Virginia in May 2013 and has been evolving ever since. Initially providing servicing and aftersales support for products manufactured by ITL in the UK and sold in to the US market, the Virginia facility is now working towards providing a domestic contract manufacturing service. It also provides a route to market for companies looking to break in to the US medical device market and acts as a sales office for ITL’s own brand of laboratory products, Vitl Life Science Solutions.

Source: http://www.itl.co.uk/